Elicio Therapeutics, Inc. — Form 10-Q Summary
Reporting period: Quarter and six months ended June 30, 2023. Financial statements are unaudited. Elicio is a clinical-stage biotechnology company developing immunotherapies, including lead candidate ELI-002, which was in Phase 1 trials. The company reported no product revenue.
Business context and comparability
On June 1, 2023, Angion Biomedica completed its merger with Elicio Operating Company, changed its name to Elicio Therapeutics, and effected a 10-for-1 reverse stock split. The merger was accounted for as a reverse recapitalization, with Former Elicio as the accounting acquirer. Accordingly, pre-merger periods reflect Former Elicio on a standalone basis; 2023 post-merger statements include Angion’s acquired business from June 2 through June 30. Comparisons therefore are not fully like-for-like. Former Elicio holders owned approximately 65.2% of the combined company on a fully diluted basis after closing.
Financial results and liquidity
| Metric | Q2 2023 | Q2 2022 | Six months 2023 | Six months 2022 |
|---|---|---|---|---|
| Revenue | None reported | None reported | None reported | None reported |
| Research and development expense | $4.9 million | $5.0 million | $10.4 million | $9.2 million |
| General and administrative expense | $2.8 million | $1.2 million | $5.2 million | $2.8 million |
| Total operating expenses | $7.8 million | $6.2 million | $15.6 million | $12.0 million |
| Net loss | $7.6 million | $7.3 million | $15.6 million | $14.4 million |
| Net loss per share, basic and diluted | $2.44 | $23.20 | $9.06 | $45.85 |
| Net cash used in operating activities | Not separately stated | Not separately stated | $17.6 million | $9.5 million |
At June 30, 2023, cash and cash equivalents were $21.7 million, with an additional $0.7 million of restricted cash. Total assets were $37.6 million, total liabilities $14.1 million, and accumulated deficit $122.6 million. Current assets were $26.2 million and current liabilities $7.6 million. Operating lease liabilities totaled $7.4 million. The balance sheet reported a $32,000 warrant liability; the merger-related promissory notes were settled in connection with the merger.
Six-month financing cash flow was $31.6 million, primarily reflecting $24.0 million of cash acquired in the merger, alongside bridge-note proceeds and transaction costs. Cash and restricted cash increased by $13.9 million during the six months.
Changes, outlook, risks, and unusual items
- Q2 operating expenses rose 25% year over year, mainly due to increased general and administrative costs related to personnel, the merger, and public-company operations. R&D expense was slightly lower in Q2, in part because of a research grant offset; for the six-month period R&D increased 13%, reflecting manufacturing and clinical-trial costs.
- Management said available cash was expected to fund planned operations through calendar year 2023, based on assumptions that could prove incorrect. The filing also states that losses, negative operating cash flows, and the need for additional capital within 12 months of issuance raise substantial doubt about the company’s ability to continue as a going concern. Additional financing is required to continue development; availability and terms are uncertain.
- The company expects continued losses and increased spending as it advances ELI-002, develops preclinical programs, pursues regulatory approvals, expands staff, and operates as a public company. No specific financial or clinical guidance beyond the stated cash-runway estimate was provided.
- Other income in Q2 included a $0.6 million gain on extinguishment of promissory notes and a $0.3 million gain from changes in fair value of embedded derivatives. Interest expense declined compared with 2022, partly due to conversion of convertible notes to preferred stock.
- Disclosure controls were deemed ineffective because of an unremediated material weakness involving accounting for complex and non-routine transactions. Management had begun remediation, including enhanced review processes. The filing notes an earlier $843,000 adjustment identified during audit work that was immaterial to the financial statements.
- A merger-related shareholder lawsuit was voluntarily dismissed in February 2023; the company warned that additional merger litigation could arise. It reported no material legal matters known to it.
Most important facts for investors to verify
- Whether the company can raise additional capital before its stated year-end 2023 cash runway expires, and how updated spending affects runway and going-concern risk.
- ELI-002 clinical progress, trial timing, and whether reported results support continued development; outcomes remain uncertain and no product is approved for sale.
- Whether the material weakness in financial reporting controls is remediated and whether subsequent filings identify further accounting issues.
- How merger accounting and the inclusion of Angion for only the post-close period affect interpretation of reported results and future comparisons.
- Potential dilution and financing terms, as well as continuing lease obligations and any new debt or warrant-related liabilities.